- Home
- EPSM vs ACIU Comparison
EPSM vs ACIU Comparison
Compare EPSM & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EPSM
- ACIU
- Stock Information
- Founded
- EPSM 2010
- ACIU 2003
- Country
- EPSM China
- ACIU Switzerland
- Employees
- EPSM N/A
- ACIU N/A
- Industry
- EPSM
- ACIU Biotechnology: Pharmaceutical Preparations
- Sector
- EPSM
- ACIU Health Care
- Exchange
- EPSM Nasdaq
- ACIU Nasdaq
- Market Cap
- EPSM 185.6M
- ACIU 173.7M
- IPO Year
- EPSM 2025
- ACIU 2016
- Fundamental
- Price
- EPSM $16.71
- ACIU $1.65
- Analyst Decision
- EPSM
- ACIU Strong Buy
- Analyst Count
- EPSM 0
- ACIU 2
- Target Price
- EPSM N/A
- ACIU $10.00
- AVG Volume (30 Days)
- EPSM 495.4K
- ACIU 106.4K
- Earning Date
- EPSM 01-01-0001
- ACIU 04-30-2025
- Dividend Yield
- EPSM N/A
- ACIU N/A
- EPS Growth
- EPSM N/A
- ACIU N/A
- EPS
- EPSM 0.02
- ACIU N/A
- Revenue
- EPSM $12,518,070.00
- ACIU $32,014,254.00
- Revenue This Year
- EPSM N/A
- ACIU N/A
- Revenue Next Year
- EPSM N/A
- ACIU $577.48
- P/E Ratio
- EPSM $812.57
- ACIU N/A
- Revenue Growth
- EPSM N/A
- ACIU 91.20
- 52 Week Low
- EPSM $4.23
- ACIU $1.43
- 52 Week High
- EPSM $17.63
- ACIU $4.98
- Technical
- Relative Strength Index (RSI)
- EPSM N/A
- ACIU 45.93
- Support Level
- EPSM N/A
- ACIU $1.65
- Resistance Level
- EPSM N/A
- ACIU $1.75
- Average True Range (ATR)
- EPSM 0.00
- ACIU 0.10
- MACD
- EPSM 0.00
- ACIU 0.01
- Stochastic Oscillator
- EPSM 0.00
- ACIU 43.55
About EPSM Epsium Enterprise Limited Ordinary Shares
Epsium Enterprise Ltd is a holding company and conducts business through its subsidiaries. It is engaged in import trading and wholesale selling of beverages in Macau. The company imports and sells a range of beverages, alcoholic beverages, and a small quantity of tea and fruit juice. The alcoholic beverages it sells include Chinese liquor, French cognac, Scottish whiskey, fine wine, Champagne, and other miscellaneous beverage alcohol.
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.